Peringatan Keamanan

Symptoms of overdose include flu-like symptoms, such as fever, fatigue, headache, nausea, diarrhoea and muscle pain.

Imiquimod

DB00724

small molecule approved investigational

Deskripsi

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.

Struktur Molekul 2D

Berat 240.3036

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) 20 hours (topical dose), 2 hours (subcutaneous dose)

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Well absorbed through skin (as a cream)

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data

1. Take with or without food.

Interaksi Obat

34 Data

Trastuzumab	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Imiquimod.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Imiquimod.
Cenobamate	The serum concentration of Imiquimod can be decreased when it is combined with Cenobamate.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Imiquimod.
Lopinavir	The serum concentration of Imiquimod can be increased when it is combined with Lopinavir.
Ritonavir	The serum concentration of Imiquimod can be increased when it is combined with Ritonavir.
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Imiquimod.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Imiquimod.
Inebilizumab	The risk or severity of infection can be increased when Imiquimod is combined with Inebilizumab.
Abametapir	The serum concentration of Imiquimod can be increased when it is combined with Abametapir.
Satralizumab	The serum concentration of Imiquimod can be decreased when it is combined with Satralizumab.
Sotorasib	The serum concentration of Imiquimod can be decreased when it is combined with Sotorasib.
Allogeneic processed thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Imiquimod.
Somatrogon	The metabolism of Imiquimod can be increased when combined with Somatrogon.
Vibrio cholerae CVD 103-HgR strain live antigen	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Imiquimod.
Mavacamten	The serum concentration of Imiquimod can be decreased when it is combined with Mavacamten.
Viloxazine	The metabolism of Imiquimod can be decreased when combined with Viloxazine.
Ivosidenib	The metabolism of Imiquimod can be increased when combined with Ivosidenib.
Dabrafenib	The serum concentration of Imiquimod can be decreased when it is combined with Dabrafenib.
Stiripentol	The metabolism of Imiquimod can be decreased when combined with Stiripentol.
Enzalutamide	The serum concentration of Imiquimod can be decreased when it is combined with Enzalutamide.
Telotristat ethyl	The serum concentration of Imiquimod can be decreased when it is combined with Telotristat ethyl.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Imiquimod.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Imiquimod.
Ublituximab	The risk or severity of infection can be increased when Ublituximab is combined with Imiquimod.
Apalutamide	The serum concentration of Imiquimod can be decreased when it is combined with Apalutamide.
Ivacaftor	The serum concentration of Imiquimod can be increased when it is combined with Ivacaftor.
Erythromycin	The serum concentration of Imiquimod can be increased when it is combined with Erythromycin.
Vadadustat	The serum concentration of Imiquimod can be increased when it is combined with Vadadustat.
Fedratinib	The serum concentration of Imiquimod can be increased when it is combined with Fedratinib.
Glofitamab	The serum concentration of Imiquimod can be increased when it is combined with Glofitamab.
Anthrax vaccine	The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Imiquimod.
Etrasimod	The risk or severity of immunosuppression can be increased when Imiquimod is combined with Etrasimod.
Cladribine	Imiquimod may increase the immunosuppressive activities of Cladribine.

Target Protein

Toll-like receptor 7 TLR7

Toll-like receptor 8 TLR8

Referensi & Sumber

Artikel (PubMed)

PMID: 17343595
van Egmond S, Hoedemaker C, Sinclair R: Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. 2007 Mar;46(3):318-9.
PMID: 11812998
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22.
PMID: 14616337
Bilu D, Sauder DN: Imiquimod: modes of action. Br J Dermatol. 2003 Nov;149 Suppl 66:5-8.
PMID: 10411278
Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999 Jan;21(1):1-14.

Contoh Produk & Brand

Produk: 47 • International brands: 13

Produk

Aldara

Cream • 50 mg/1000mg • Topical • US • Approved
Aldara

Cream • 50 mg/1000mg • Topical • US • Approved
Aldara

Cream • 50 mg/1000mg • Topical • US • Approved
Aldara

Cream • 50 mg/1g • Topical • US • Approved
Aldara

Cream • 5 %(w/w) • Cutaneous • EU • Approved
Aldara

Cream • 5 %(w/w) • Cutaneous • EU • Approved
Aldara P

Cream • 5 % • Topical • Canada • Approved
Apo-imiquimod

Cream • 5 % w/w • Topical • Canada • Generic • Approved

Menampilkan 8 dari 47 produk.

International Brands

Beselna — Mochida
Imimore — Panalab
Imiquad — Glenmark
Labimiq — ITF - Labomed
Li Di — Mingxin Pharmaceutical
Miquimod — Lazar
Nan Bo — Topfond Pharmaceutical
Nilwart — Dr. Reddy's
Omiquidar — Darier
Tian Rui — Yangtze River Pharma

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.